RO8
2022-01-21
Sharing
Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么BioNTech、Moderna、Novavax和Ocugen股票本周暴跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":630801944,"tweetId":"630801944","gmtCreate":1642760270869,"gmtModify":1642760271122,"author":{"id":3585981947031986,"idStr":"3585981947031986","authorId":3585981947031986,"authorIdStr":"3585981947031986","name":"RO8","avatar":"https://static.tigerbbs.com/1f744cb66900b3865c3ed1da7364ddce","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.10%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Sharing</p></body></html>","htmlText":"<html><head></head><body><p>Sharing</p></body></html>","text":"Sharing","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630801944","repostId":1100606079,"repostType":4,"repost":{"id":"1100606079","kind":"news","pubTimestamp":1642731768,"share":"https://www.laohu8.com/m/news/1100606079?lang=zh_CN&edition=full","pubTime":"2022-01-21 10:22","market":"us","language":"en","title":"Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么BioNTech、Moderna、Novavax和Ocugen股票本周暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100606079","media":"Motley Fool","summary":"What happenedShares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)s","content":"<p><html><head></head><body><b>What happened</b></p><p><blockquote><html><head></head><body><b>发生了什么</b></body></html></blockquote></p><p>Shares of several COVID-19 vaccine makers are plunging this week.<b>BioNTech</b>(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.<b>Moderna</b>'s(NASDAQ:MRNA)shares were sinking 17.2%.<b>Novavax</b>(NASDAQ:NVAX) and <b>Ocugen</b>(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&P Global Market Intelligence.</p><p><blockquote>几家COVID-19疫苗制造商的股价本周暴跌。<b>BioNTech</b>（纳斯达克：BNTX）股价遭受最严重的打击，截至周四收盘下跌19.7%。<b>现代</b>（纳斯达克股票代码：MRNA）股价下跌17.2%。<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）股价分别下跌18.5%和16.2%。所有这些下降都是基于标准普尔全球市场情报的数据。</blockquote></p><p>There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization's (WHO) chief scientist also stated publicly on Tuesday that there's no evidence that booster doses are needed for healthy children and adolescents.</p><p><blockquote>这些疫苗股的大幅抛售背后有多重因素。也许最重要的是，投资者似乎将目光投向了当前COVID-19病例激增之外，未来对疫苗的需求可能会降低。世界卫生组织（世卫组织）首席科学家周二也公开表示，没有证据表明健康的儿童和青少年需要加强剂量。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3d26561931e10f5ca9eea3a42da88654\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p>BioNTech's shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,<b>Pfizer</b>(NYSE:PFE), isn't effective at preventing infections by the coronavirus omicron variant.</p><p><blockquote>由于本周在以色列进行的一项临床研究公布了新结果，BioNTech的股价跌幅最大。这项研究发现，BioNTech及其合作伙伴开发的新冠疫苗Comirnaty的第四剂加强针，<b>辉瑞</b>（纽约证券交易所股票代码：PFE），不能有效预防冠状病毒奥密克戎变种的感染。</blockquote></p><p>This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna's COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won't be effective at preventing infection by omicron either.</p><p><blockquote>这一消息似乎也对Moderna产生了负面影响。与辉瑞-BioNTech疫苗一样，Moderna的新冠疫苗Spikevax采用了信使RNA（mRNA）技术。投资者似乎担心第四剂Spikevax加强剂也无法有效预防奥密克戎病毒感染。</blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>The prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.</p><p><blockquote>投资者应该关注对COVID-19疫苗需求减少的前景。这种情况将意味着BioNTech和Moderna的收入下降，这两家公司已经在美国和世界各地上市了COVID-19疫苗。</blockquote></p><p>It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax's COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn't secured authorizations in either country.</p><p><blockquote>这也可能意味着Novavax和Ocugen的艰难攀登。Novavax的COVID-19疫苗最近已在多个国家获得授权或批准，但尚未在美国获得授权或批准。Ocugen拥有在美国和加拿大销售科瓦克辛的权利，但尚未在这两个国家获得授权。</blockquote></p><p>However, it's too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization's COVID-19 technical lead, Maria Van Kerkhove, stated, "We're hearing a lot of people suggest that omicron is the last variant, that it's over after this. And that is not the case because this virus is circulating at a very intense level around the world."</p><p><blockquote>然而，现在知道疫苗需求是否真的会大幅下降还为时过早。世界卫生组织（WHO）本周警告称，在当前的奥密克戎浪潮消退后，很可能会出现新的冠状病毒变种。该组织的COVID-19技术负责人玛丽亚·范·科霍夫表示，“我们听到很多人认为奥密克戎是最后一个变种，在此之后就结束了。但事实并非如此，因为这种病毒正在以非常强烈的速度传播。”世界各地的水平。”</blockquote></p><p>As for the WHO's take that boosters for healthy children and adolescents aren't necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.</p><p><blockquote>至于世卫组织认为健康儿童和青少年没有必要使用增强剂，各国是否会同意还有待观察。美国政府继续鼓励12岁及以上的青少年接受辉瑞-BioNTech疫苗的第三剂加强剂。</blockquote></p><p>But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn't as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.</p><p><blockquote>但是来自以色列的关于第四剂Comirnaty的新数据呢？这可能并不像乍一看那么令人担忧。辉瑞和BioNTech预计将在3月份之前准备好针对奥密克戎的疫苗。Moderna正在开发一种针对奥密克戎病毒变种的疫苗。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p>The most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.</p><p><blockquote>到目前为止，投资者现在关注的最重要的事情是COVID-19大流行接下来会发生什么。新冠病毒变种的传播可能会彻底改变这些公司的市场动态。</blockquote></p><p>Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.</p><p><blockquote>尽管股票表现惨淡，但Novavax最近实际上还是迎来了一些好消息。过去几天，该公司的COVID-19疫苗在法国和澳大利亚获得了批准。Novavax预计将很快完成在美国的紧急使用授权（EUA）申请。</blockquote></p><p>Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.</p><p><blockquote>Ocugen已提交美国儿童科瓦克辛EUA。然而，该公司仍在等待美国解除临床搁置。美国食品药品监督管理局计划对该疫苗进行后期临床研究。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么BioNTech、Moderna、Novavax和Ocugen股票本周暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么BioNTech、Moderna、Novavax和Ocugen股票本周暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2022-01-21 10:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><b>What happened</b></p><p><blockquote><html><head></head><body><b>发生了什么</b></body></html></blockquote></p><p>Shares of several COVID-19 vaccine makers are plunging this week.<b>BioNTech</b>(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.<b>Moderna</b>'s(NASDAQ:MRNA)shares were sinking 17.2%.<b>Novavax</b>(NASDAQ:NVAX) and <b>Ocugen</b>(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&P Global Market Intelligence.</p><p><blockquote>几家COVID-19疫苗制造商的股价本周暴跌。<b>BioNTech</b>（纳斯达克：BNTX）股价遭受最严重的打击，截至周四收盘下跌19.7%。<b>现代</b>（纳斯达克股票代码：MRNA）股价下跌17.2%。<b>Novavax</b>（纳斯达克：NVAX）和<b>奥库根</b>（纳斯达克：OCGN）股价分别下跌18.5%和16.2%。所有这些下降都是基于标准普尔全球市场情报的数据。</blockquote></p><p>There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization's (WHO) chief scientist also stated publicly on Tuesday that there's no evidence that booster doses are needed for healthy children and adolescents.</p><p><blockquote>这些疫苗股的大幅抛售背后有多重因素。也许最重要的是，投资者似乎将目光投向了当前COVID-19病例激增之外，未来对疫苗的需求可能会降低。世界卫生组织（世卫组织）首席科学家周二也公开表示，没有证据表明健康的儿童和青少年需要加强剂量。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3d26561931e10f5ca9eea3a42da88654\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p>BioNTech's shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,<b>Pfizer</b>(NYSE:PFE), isn't effective at preventing infections by the coronavirus omicron variant.</p><p><blockquote>由于本周在以色列进行的一项临床研究公布了新结果，BioNTech的股价跌幅最大。这项研究发现，BioNTech及其合作伙伴开发的新冠疫苗Comirnaty的第四剂加强针，<b>辉瑞</b>（纽约证券交易所股票代码：PFE），不能有效预防冠状病毒奥密克戎变种的感染。</blockquote></p><p>This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna's COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won't be effective at preventing infection by omicron either.</p><p><blockquote>这一消息似乎也对Moderna产生了负面影响。与辉瑞-BioNTech疫苗一样，Moderna的新冠疫苗Spikevax采用了信使RNA（mRNA）技术。投资者似乎担心第四剂Spikevax加强剂也无法有效预防奥密克戎病毒感染。</blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>The prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.</p><p><blockquote>投资者应该关注对COVID-19疫苗需求减少的前景。这种情况将意味着BioNTech和Moderna的收入下降，这两家公司已经在美国和世界各地上市了COVID-19疫苗。</blockquote></p><p>It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax's COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn't secured authorizations in either country.</p><p><blockquote>这也可能意味着Novavax和Ocugen的艰难攀登。Novavax的COVID-19疫苗最近已在多个国家获得授权或批准，但尚未在美国获得授权或批准。Ocugen拥有在美国和加拿大销售科瓦克辛的权利，但尚未在这两个国家获得授权。</blockquote></p><p>However, it's too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization's COVID-19 technical lead, Maria Van Kerkhove, stated, "We're hearing a lot of people suggest that omicron is the last variant, that it's over after this. And that is not the case because this virus is circulating at a very intense level around the world."</p><p><blockquote>然而，现在知道疫苗需求是否真的会大幅下降还为时过早。世界卫生组织（WHO）本周警告称，在当前的奥密克戎浪潮消退后，很可能会出现新的冠状病毒变种。该组织的COVID-19技术负责人玛丽亚·范·科霍夫表示，“我们听到很多人认为奥密克戎是最后一个变种，在此之后就结束了。但事实并非如此，因为这种病毒正在以非常强烈的速度传播。”世界各地的水平。”</blockquote></p><p>As for the WHO's take that boosters for healthy children and adolescents aren't necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.</p><p><blockquote>至于世卫组织认为健康儿童和青少年没有必要使用增强剂，各国是否会同意还有待观察。美国政府继续鼓励12岁及以上的青少年接受辉瑞-BioNTech疫苗的第三剂加强剂。</blockquote></p><p>But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn't as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.</p><p><blockquote>但是来自以色列的关于第四剂Comirnaty的新数据呢？这可能并不像乍一看那么令人担忧。辉瑞和BioNTech预计将在3月份之前准备好针对奥密克戎的疫苗。Moderna正在开发一种针对奥密克戎病毒变种的疫苗。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p>The most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.</p><p><blockquote>到目前为止，投资者现在关注的最重要的事情是COVID-19大流行接下来会发生什么。新冠病毒变种的传播可能会彻底改变这些公司的市场动态。</blockquote></p><p>Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.</p><p><blockquote>尽管股票表现惨淡，但Novavax最近实际上还是迎来了一些好消息。过去几天，该公司的COVID-19疫苗在法国和澳大利亚获得了批准。Novavax预计将很快完成在美国的紧急使用授权（EUA）申请。</blockquote></p><p>Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.</p><p><blockquote>Ocugen已提交美国儿童科瓦克辛EUA。然而，该公司仍在等待美国解除临床搁置。美国食品药品监督管理局计划对该疫苗进行后期临床研究。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2022/01/20/why-biontech-moderna-novavax-and-ocugen-stocks-are/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","OCGN":"Ocugen","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/01/20/why-biontech-moderna-novavax-and-ocugen-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100606079","content_text":"What happenedShares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.Moderna's(NASDAQ:MRNA)shares were sinking 17.2%.Novavax(NASDAQ:NVAX) and Ocugen(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&P Global Market Intelligence.There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization's (WHO) chief scientist also stated publicly on Tuesday that there's no evidence that booster doses are needed for healthy children and adolescents.IMAGE SOURCE: GETTY IMAGES.BioNTech's shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,Pfizer(NYSE:PFE), isn't effective at preventing infections by the coronavirus omicron variant.This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna's COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won't be effective at preventing infection by omicron either.So whatThe prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax's COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn't secured authorizations in either country.However, it's too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization's COVID-19 technical lead, Maria Van Kerkhove, stated, \"We're hearing a lot of people suggest that omicron is the last variant, that it's over after this. And that is not the case because this virus is circulating at a very intense level around the world.\"As for the WHO's take that boosters for healthy children and adolescents aren't necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn't as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.Now whatThe most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9,"OCGN":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":814,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/630801944"}
精彩评论